United Kingdom · Question · Written question
UIN 3472
Cystic Fibrosis: Drugs
Introduced
23 November 2023
Last action
30 November 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
30 November 2023
Summary
To ask the Secretary of State for Health and Social Care, with reference to the draft guidance published by NICE entitled Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis, published on 3 November
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
23 November 2023
Written question
To ask the Secretary of State for Health and Social Care, with reference to the draft guidance published by NICE entitled Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis, published on 3 November
Source: Commons
30 November 2023
Answer
The National Institute for Health and Care Excellence (NICE) has recently consulted on its draft recommendations on the use of lumacaftor–ivacaftor (Orkambi), tezacaftor–ivacaftor (Symkevi) and ivacaftor–tezacaftor–elexacaftor (Kaftrio) and has not yet pu...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-11-23/3472
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1672696
- uk · wq-1672696 · source updated 30 November 2023